Elutia Announces Strong First Quarter 2025 Financial Results Driven by 84% Sequential Growth in EluPro™ Sales
- 84% sequential growth in EluPro sales, driving 31% year-over-year BioEnvelope revenue growth to $3.1 million
- Strategic partnership with Boston Scientific adding 900+ sales professionals nationwide
- Over 125 value analysis committee approvals and seven GPO contracts secured
- Strengthened financial position with $15.0 million raised through registered direct offering
- Regained full commercial rights to cardiovascular portfolio products
- 10% decrease in overall net sales to $6.0 million
- Decline in gross margin to 40.7% from 42.5% year-over-year
- Operating loss of $7.9 million
- Adjusted EBITDA loss of $3.3 million
- Significant decline in SimpliDerm sales from $3.6M to $2.6M
Insights
Elutia shows 84% sequential EluPro growth and Boston Scientific partnership, though overall revenue declined 10% amid product transition.
Elutia's Q1 2025 results reveal strong momentum for their flagship EluPro product amid a broader company transition. The BioEnvelope segment, which includes EluPro, achieved
The overall financial picture shows a company in transition. Total sales decreased
The new Boston Scientific partnership represents a significant strategic win that should accelerate EluPro's market penetration. This arrangement expands Elutia's commercial reach to over 900 sales professionals nationwide while allowing the company to maintain full end-user revenue. Boston Scientific is already generating sales in over 50 hospitals, suggesting rapid integration of the partnership.
Market access metrics are encouraging, with 125+ value analysis committee approvals and seven GPO contracts providing broad national coverage. These institutional endorsements typically translate to sustained sales growth in the medical device sector.
Financially, Elutia has strengthened its position by raising
EluPro's rapid clinical adoption and Boston Scientific partnership validate Elutia's innovative drug-eluting biomatrix technology in the cardiac device market.
Elutia's EluPro technology represents a significant advancement in cardiac implantable electronic device (CIED) procedures. The
The 125+ value analysis committee approvals is particularly noteworthy, as VACs typically require compelling clinical and economic evidence before authorizing new products. These approvals indicate that hospital systems are recognizing tangible benefits that justify adoption despite healthcare's typically conservative approach to new technologies.
Boston Scientific's partnership substantially validates EluPro's clinical value proposition. Major medical device manufacturers rarely partner with smaller companies unless the technology offers meaningful clinical differentiation and market potential. The rapid deployment across 50+ hospitals through this partnership suggests strong physician interest.
The 2025 Edison Award and continued investment in clinical evidence through the real-world outcomes study demonstrate Elutia's commitment to scientific validation. The peer-reviewed data on EluPro's broad-spectrum antibacterial efficacy addresses a crucial concern in CIED procedures, where infections remain a serious complication.
The company's strategic decision to regain full commercial rights to their cardiovascular portfolio (ProxiCor, Tyke, and VasCure) while shifting to a contractor-based sales model reflects a focused approach to resource allocation, prioritizing the EluPro platform while maintaining revenue streams from established products.
- New Boston Scientific distribution partnership now underway -
- Conference call today at 5:00 p.m. ET / 2:00 p.m. PT -
SILVER SPRING, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Elutia Inc. (Nasdaq: ELUT) (“Elutia” or the “Company”), a pioneer in drug-eluting biomatrix technologies, today reported strong first-quarter results for 2025 and highlighted key developments driving the adoption of EluPro™. In its first quarter post-launch, EluPro demonstrated strong momentum, establishing its position as a groundbreaking solution for cardiac implantable electronic device (CIED) procedures.
Business Highlights:
- The EluPro™ Revolution is Now Underway: In its first full quarter post-launch, EluPro experienced an
84% sequential increase, driving31% year-over-year BioEnvelope revenue growth, totaling$3.1 million ; EluPro accounted for approximately52% of BioEnvelope sales in the quarter. - Robust Market Access of EluPro: Value analysis committee (VAC) approvals now exceed 125, with hospitals actively ordering; two new GPO contracts signed in Q1 bring total coverage to seven with broad national reach.
- New Strategic Partnership with Boston Scientific (BSC): Expected to accelerate adoption starting in Q2 2025; Combined commercial footprint now exceeds 900 sales professionals nationwide, with BSC reps driving VAC approvals and in-procedure adoption of EluPro; Elutia captures full end-user revenue while leveraging BSC case coverage under a favorable economic model; initial training is complete and BSC is already generating sales in over 50 hospitals.
- EluPro Gaining Recognition Through Targeted Marketing: Prominent presence at Heart Rhythm Society 2025, launching a new national campaign: ‘Putting an End to Unnecessary Roughness – Feel the Difference Biology Makes.’
- Scientific Leadership Driving Credibility and Adoption: EluPro received a 2025 Edison Award for innovation in post-surgical recovery; the first patient was enrolled in the real-world outcomes study; and new peer-reviewed data further validated EluPro’s broad-spectrum antibacterial efficacy.
- Cardiovascular Portfolio Update: Elutia regained full commercial rights to ProxiCor™, Tyke™, and VasCure™, now sold through a lean contractor-based model expected to drive top-line growth and immediately improve cash flow.
- Strengthened Financial Position: Raised
$15.0 million in gross proceeds through a registered direct offering; amended SWK loan terms to allow full PIK interest and potential access to an additional$5 million term loan; and revised the Ligand agreement to accept equity in lieu of cash, reducing outflows by$2.2 million in H1 2025.
“With an
First Quarter 2025 Financial Results
For the three-month period ended March 31, 2025, as compared to the same period of 2024:
- Net sales for BioEnvelope products, including both EluPro and CanGaroo, increased by
31% , totaling$3.1 million compared to$2.4 million in Q1 2024, reflecting strong and accelerating sales of EluPro. - Net sales of SimpliDerm were
$2.6 million , compared to$3.6 million in Q1 2024. - Net sales of Cardiovascular products were
$0.3 million , compared to$0.8 million in Q1 2024. - Overall net sales decreased
10% to$6.0 million , compared to$6.7 million . - Gross margin on a GAAP basis was
40.7% , compared to42.5% - Adjusted gross margin (a non-GAAP measure which excludes non-cash amortization of intangibles) was
54.8% , compared to55.2% . A reconciliation of GAAP gross margin to adjusted gross margin is included in the accompanying financial tables. - Total operating expenses were
$10.4 million , compared to$11.3 million . - Loss from operations was
$7.9 million , compared to$8.5 million . - Adjusted EBITDA (a non-GAAP measure that excludes from net loss certain non-operating, non-cash and non-recurring items) was a loss of
$3.3 million , compared to a loss of$3.6 million . A reconciliation of net loss to adjusted EBITDA is included in the accompanying financial tables. - Cash balance as of March 31, 2025, was
$17.4 million .
Conference Call
Elutia will host a conference call today at 5:00 p.m. Eastern Time / 2:00 p.m. Pacific Time to discuss its first quarter 2025 financial results and performance.
The conference call can be accessed using the following information:
Webcast: Click here
U.S. Investors: 877-407-8029
International Investors: 201-689-8029
Conference ID: 13753035
About Elutia
Elutia develops and commercializes drug-eluting biomatrix products to improve compatibility between medical devices and the patients who need them. With a growing population in need of implantable technologies, Elutia’s mission is humanizing medicine so patients can thrive without compromise. For more information, visit www.Elutia.com.
Non-GAAP Disclosure
In addition to the Company's financial results determined in accordance with U.S. GAAP, the Company provides non-GAAP measures that it determines to be useful in evaluating its operating performance and liquidity. The Company presents in this press release the following non-GAAP financial measures: earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted earnings before interest, taxes, depreciation and amortization (“adjusted EBITDA”), adjusted gross margin and adjusted gross profit. The Company defines EBITDA as GAAP net loss excluding interest expense, income tax expense, depreciation and amortization, and the Company defines adjusted EBITDA as EBITDA excluding stock-based compensation, FiberCel and VBM litigation costs, loss or gain on revaluation of warrant liability, warrant issuance expenses and gain on revaluation of revenue interest obligation. The Company defines adjusted gross profit and adjusted gross margin as GAAP gross profit and GAAP gross margin, respectively, excluding amortization of acquired intangible assets. The amortization of these intangible assets will recur in future periods until such intangible assets have been fully amortized. Management believes that presentation of non-GAAP financial measures provides useful supplemental information to investors and facilitates the analysis of the Company's core operating results and comparison of operating results across reporting periods. The Company uses this non-GAAP financial information to establish budgets, manage the Company's business, and set incentive and compensation arrangements. Non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-GAAP financial information is presented for supplemental information purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with U.S. GAAP. For a reconciliation of these non-GAAP measures to GAAP, see below “Non-GAAP Reconciliations of EBITDA and Adjusted EBITDA” and “Non-GAAP Reconciliations of Adjusted Gross Profit and Adjusted Gross Margin.”
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements can be identified by words such as “projects,” “may,” “will,” “could,” “would,” “should,” “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “potential,” “promise” or similar references to future periods. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including any statements and information concerning the market reception of EluPro, including the timing and anticipated success thereof. These forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to us. Such beliefs and assumptions may or may not prove to be correct. Additionally, such forward-looking statements are subject to a number of known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied in the forward-looking statements, including, but not limited to the following: our ability to successfully commercialize, market and sell our EluPro product; our ability to continue as a going concern; our ability to achieve or sustain profitability; the risk of product liability claims and our ability to obtain or maintain adequate product liability insurance; our ability to defend against the various lawsuits and claims related to our recalled FiberCel and other viable bone matrix products and avoid a material adverse financial consequence from those lawsuits and claims; our ability to prevail in lawsuits and claims seeking indemnity, contribution and insurance coverage for FiberCel and other viable bone matrix product liabilities; the continued and future acceptance of our products by the medical community; our ability to enhance our products, expand our product indications and develop, acquire and commercialize additional product offerings; our dependence on our commercial partners and independent sales agents to generate a substantial portion of our net sales; our dependence on a limited number of third-party suppliers and manufacturers, which, in certain cases are exclusive suppliers for products essential to our business; our ability to successfully realize the anticipated benefits of the November 2023 sale of our Orthobiologics business; physician awareness of the distinctive characteristics, benefits, safety, clinical efficacy and cost-effectiveness of our products; our ability to compete against other companies, most of which have longer operating histories, more established products and/or greater resources than we do; pricing pressure as a result of cost-containment efforts of our customers, purchasing groups, third-party payors and governmental organizations that could adversely affect our sales and profitability; our ability to obtain regulatory approval or other marketing authorizations by the FDA and comparable foreign authorities for our products and product candidates; our ability to obtain, maintain and adequately protect our intellectual property rights; and other important factors which can be found in the “Risk Factors” section of Elutia’s public filings with the Securities and Exchange Commission (“SEC”), including Elutia’s Annual Report on Form 10-K for the year ended December 31, 2024, as such factors may be updated from time to time in Elutia’s other filings with the SEC, including Elutia’s Quarterly Reports on Form 10-Q, accessible on the SEC’s website at www.sec.gov and the Investor Relations page of Elutia’s website at https://investors.elutia.com. Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. Any forward-looking statement made by Elutia in this press release is based only on information currently available and speaks only as of the date on which it is made. Except as required by applicable law, Elutia expressly disclaims any obligations to publicly update any forward-looking statements, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.
Investors:
Matt Steinberg
FINN Partners
matt.steinberg@finnpartners.com
| ELUTIA INC. | |||||||
| CONSOLIDATED BALANCE SHEET DATA | |||||||
| (Unaudited, in thousands) | |||||||
| Assets | March 31, 2025 | December 31, 2024 | |||||
| Current assets: | |||||||
| Cash | $ | 17,358 | $ | 13,239 | |||
| Accounts receivable, net | 2,860 | 2,276 | |||||
| Inventory | 4,286 | 3,911 | |||||
| Receivables of litigation costs | 3,893 | 4,760 | |||||
| Prepaid expense and other current assets | 1,620 | 1,986 | |||||
| Total current assets | 30,017 | 26,172 | |||||
| Property and equipment, net | 1,031 | 773 | |||||
| Intangible assets, net | 7,424 | 8,273 | |||||
| Operating lease right-of-use assets, and other | 826 | 909 | |||||
| Total assets | $ | 39,298 | $ | 36,127 | |||
| Liabilities and Stockholders' Deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable and accrued expenses and other current liabilities | $ | 10,608 | $ | 11,253 | |||
| Current portion of long-term debt | 2,500 | 1,250 | |||||
| Current portion of revenue interest obligation | 5,500 | 4,400 | |||||
| Contingent liability for legal proceedings | 17,808 | 20,432 | |||||
| Current operating lease liabilities | 435 | 460 | |||||
| Total current liabilities | 36,851 | 37,795 | |||||
| Long-term debt | 21,762 | 22,603 | |||||
| Long-term revenue interest obligation | 4,735 | 5,490 | |||||
| Warrant liability | 12,089 | 16,076 | |||||
| Other long-term liabilities | 319 | 423 | |||||
| Total liabilities | 75,756 | 82,387 | |||||
| Stockholders' equity (deficit): | |||||||
| Common stock | 41 | 35 | |||||
| Additional paid-in capital | 197,027 | 183,298 | |||||
| Accumulated deficit | (233,526 | ) | (229,593 | ) | |||
| Total stockholders' deficit | (36,458 | ) | (46,260 | ) | |||
| Total liabilities and stockholders' deficit | $ | 39,298 | $ | 36,127 | |||
| ELUTIA INC. | |||||||
| CONSOLIDATED STATEMENT OF OPERATIONS | |||||||
| (Unaudited, in thousands, except share and per share data) | |||||||
| Three months ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net sales | $ | 6,030 | $ | 6,694 | |||
| Cost of goods sold | 3,573 | 3,851 | |||||
| Gross profit | 2,457 | 2,843 | |||||
| Operating expenses: | |||||||
| Sales and marketing | 3,031 | 3,309 | |||||
| General and administrative | 3,871 | 5,056 | |||||
| Research and development | 905 | 1,172 | |||||
| Litigation costs, net | 2,572 | 1,785 | |||||
| Total operating expenses | 10,379 | 11,322 | |||||
| Loss from operations | (7,922 | ) | (8,479 | ) | |||
| Interest expense | 1,085 | 1,313 | |||||
| Other (income) expense, net | (5,082 | ) | 8,194 | ||||
| Loss before provision of income taxes | (3,925 | ) | (17,986 | ) | |||
| Income tax expense | 8 | 8 | |||||
| Net loss | $ | (3,933 | ) | $ | (17,994 | ) | |
| Net loss per share - basic | $ | (0.10 | ) | $ | (0.75 | ) | |
| Net loss per share - diluted | $ | (0.21 | ) | $ | (0.75 | ) | |
| Weighted average common shares outstanding - basic | 38,616,207 | 23,912,326 | |||||
| Weighted average common shares outstanding - diluted | 42,913,111 | 23,912,326 | |||||
| ELUTIA INC. | |||||||
| NON-GAAP GROSS PROFIT AND NON-GAAP GROSS MARGIN RECONCILIATIONS | |||||||
| (Unaudited, in thousands, except share and per share data) | |||||||
| Three months ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net sales | $ | 6,030 | $ | 6,694 | |||
| Gross profit | 2,457 | 2,843 | |||||
| Intangible asset amortization expense | 849 | 849 | |||||
| Adjusted gross profit (Non-GAAP) | $ | 3,306 | $ | 3,692 | |||
| Gross margin | 40.7 | % | 42.5 | % | |||
| Adjusted gross margin percentage (Non-GAAP) | 54.8 | % | 55.2 | % | |||
| ELUTIA INC. | |||||||
| EBITDA AND ADJUSTED EBITDA RECONCILIATIONS | |||||||
| (Unaudited, in thousands, except share and per share data) | |||||||
| Three months ended March 31, | |||||||
| 2025 | 2024 | ||||||
| Net loss | $ | (3,933 | ) | $ | (17,994 | ) | |
| Interest expense(1) | 1,085 | 1,313 | |||||
| Provision (benefit) for income taxes | 8 | 8 | |||||
| Depreciation and amortization | 868 | 864 | |||||
| Earnings before interest, taxes, depreciation and amortization (“EBITDA”) (Non-GAAP) | (1,972 | ) | (15,809 | ) | |||
| Stock-based compensation | 1,211 | 2,197 | |||||
| Litigation costs, net(2) | 2,572 | 1,785 | |||||
| (Gain) loss on revaluation of warrant liability(3) | (5,187 | ) | 9,636 | ||||
| Warrant issuance expenses | 105 | - | |||||
| Gain on revaluation of revenue interest obligation(4) | - | (1,442 | ) | ||||
| Adjusted EBITDA (Non-GAAP) | $ | (3,271 | ) | $ | (3,633 | ) | |
| (1) | Represents interest expense recorded on all outstanding long-term debt as well as the revenue interest obligation. |
| (2) | Represents litigation costs consisting primarily of legal fees and the estimated and actual costs to resolve the outstanding FiberCel and VBM litigation cases offset by the amounts recovered and recoverable under insurance, indemnity and contribution agreements for such costs. |
| (3) | Represents non-cash expense attributable to the revaluation of Common Warrants and Prefunded Warrants issued in connection with a private offering in September 2023 and registered direct offerings in June 2024 and February 2025 |
| (4) | Represents the gain on the revaluation of the revenue interest obligation. At each reporting period, the value of the revenue interest obligation is re-measured based on current estimates of future payments, with changes to be recorded in the consolidated statements of operations using the catch-up method. |
This press release was published by a CLEAR® Verified individual.
FAQ
What was Elutia's (ELUT) revenue growth for EluPro in Q1 2025?
How will the Boston Scientific partnership benefit Elutia (ELUT)?
What was Elutia's (ELUT) total revenue for Q1 2025?
How much cash did Elutia (ELUT) have as of March 31, 2025?
What was Elutia's (ELUT) gross margin in Q1 2025?
